Waters Corp

WAT

Market cap $37.1B

Waters Corporation remains a Hold as valuation concerns are balanced by ongoing synergy capture from its Becton, Dickinson acquisition. WAT's Q1 pro forma sales rose to $1.54B, with legacy revenue up 13% and recurring revenue surging 123%, signaling broad-based growth. Synergy realization is on track, with $55M+ cost savings and $50M revenue synergies targeted for 2026, supporting incremental EBITDA gains.

MILFORD, Mass., July 2, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) will hold its Q2 2026 financial results conference call on Tuesday, August 4, 2026, at 8:00 a.m.

LONDON--(BUSINESS WIRE)--IMU Biosciences, a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand, diagnose, and treat disease, and Waters Corporation (NYSE: WAT) today announced a strategic partnership to accelerate the development of IMU's next-generation AI-powered High Definition (HD) Immunology platform.The partnership brings together Waters Biosciences' advanced flow cytometry and single-cell technologies,1 including BD FACSDiscover Cell Analyzer.

Integrates heat flow, evolved gas, and electrochemical analysis in a single experiment, enabling earlier insights into thermal runaway. Unique whole-cell design eliminates cell teardown, reducing sample preparation time by >90%.

Faster run times for GLP-1, insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottlenecks. Delivers up to 2x increase in resolving power and sensitivity to identify and track low-level impurities for improved regulatory readiness.

Waters (WAT) reported earnings 30 days ago. What's next for the stock?

Waters Corporation (WAT) Presents at Jefferies Global Healthcare Conference 2026 Transcript

FDA 510(k)-cleared BD BACTEC™ FXI Culture System now available to U.S. market, enabling broader access to confident bloodstream infection diagnostics. Achieves a 3-hour faster time to detection (~15% reduction) versus the prior-generation system, per clinical study data, enabling earlier targeted sepsis prevention.

>10x step-change in MS/MS sensitivity paired with multipass Cyclic™ Ion Mobility Spectrometry (IMS) reveals subtle biological differences for earlier, previously unattainable detection of disease signals. 50% extended upper mass range and comprehensive suite of structural tools advance the development of next-generation biotherapeutics.

Delivers up to 20x improvement in MS/MS sensitivity and 2x faster acquisition speeds, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows. Identifies up to 40% more lipids by LC‑MS/MS than the leading alternative benchtop high‑resolution mass spectrometer, advancing lipidomics research and disease understanding.